CytomX Therapeutics, Inc. (CTMX)
NASDAQ: CTMX · Real-Time Price · USD
3.360
+0.040 (1.20%)
Aug 5, 2026, 10:22 AM EDT - Market open
CytomX Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 28.83 | 12.67 | 38.05 | 17.17 | 193.65 | 205.53 |
Short-Term Investments | 317.88 | 124.39 | 62.57 | 157.34 | - | 99.7 |
Cash & Short-Term Investments | 346.71 | 137.05 | 100.62 | 174.51 | 193.65 | 305.23 |
Cash Growth | 334.00% | 36.20% | -42.34% | -9.88% | -36.55% | -3.45% |
Accounts Receivable | 0.65 | 2.01 | 3.1 | 3.43 | 35.99 | 0.79 |
Other Current Assets | 5.74 | 4.86 | 3.58 | 5 | 7.47 | 4.29 |
Total Current Assets | 353.1 | 143.92 | 107.31 | 182.94 | 237.1 | 310.3 |
Net Property, Plant & Equipment | 3.35 | 4.7 | 10.6 | 16.18 | 21.02 | 25.32 |
Other Intangible Assets | 0.4 | 0.44 | 0.58 | 0.73 | 0.88 | 1.02 |
Goodwill | 0.95 | 0.95 | 0.95 | 0.95 | 0.95 | 0.95 |
Other Long-Term Assets | 1.56 | 1.56 | 1.09 | 1 | 0.94 | 1.82 |
Total Assets | 359.36 | 151.57 | 120.53 | 201.79 | 260.89 | 339.41 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 1.37 | 1.3 | 1.09 | 1.46 | 2.81 | 2.82 |
Accrued Expenses | 11.92 | 14.2 | 12.34 | 17.6 | 24.45 | 34.24 |
Current Portion of Leases | 2.86 | 4.24 | 5.15 | 4.59 | 4.08 | - |
Unearned Revenue | 17.88 | 26.88 | 67.2 | 132.27 | 121.27 | 40.82 |
Total Current Liabilities | 34.02 | 46.62 | 85.77 | 155.91 | 152.61 | 77.87 |
Long-Term Leases | - | - | 4.24 | 9.39 | 13.98 | 18.06 |
Other Long-Term Liabilities | 5.39 | 5.94 | 30.98 | 83.94 | 180.06 | 243.94 |
Total Long-Term Liabilities | 5.39 | 5.94 | 35.22 | 93.33 | 194.03 | 262 |
Total Liabilities | 39.41 | 52.56 | 120.99 | 249.24 | 346.64 | 339.87 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0 | 0 | 0 | 0 | 0 | 0 |
Additional Paid-in Capital | 1,050 | 810.84 | 691.1 | 675.91 | 637.12 | 623.34 |
Accumulated Other Comprehensive Income | 0.1 | 0.11 | 0.03 | 0.1 | 0.01 | -0.24 |
Retained Earnings | -730.2 | -711.95 | -691.58 | -723.45 | -722.88 | -623.56 |
Shareholders' Equity | 319.94 | 99.01 | -0.46 | -47.45 | -85.75 | -0.46 |
Total Liabilities & Equity | 359.36 | 151.57 | 120.53 | 201.79 | 260.89 | 339.41 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 2.86 | 4.24 | 9.39 | 13.97 | 18.06 | 18.06 |
Net Cash (Debt) | 343.85 | 132.81 | 91.24 | 160.54 | 175.59 | 287.17 |
Net Cash Growth | 379.32% | 45.57% | -43.17% | -8.58% | -38.85% | -2.47% |
Net Cash Per Share | 2.15 | 0.96 | 1.08 | 2.17 | 2.67 | 4.48 |
Book Value | 319.94 | 99.01 | -0.46 | -47.45 | -85.75 | -0.46 |
Book Value Per Share | 2.00 | 0.72 | -0.01 | -0.64 | -1.30 | -0.01 |
Tangible Book Value | 318.59 | 97.62 | -1.99 | -49.13 | -87.58 | -2.43 |
Tangible Book Value Per Share | 1.99 | 0.71 | -0.02 | -0.67 | -1.33 | -0.04 |